jenis

Jinse Finance reported that on June 30, two senior executives from JPMorgan stated that if stablecoin innovation allows for interest generation and yields, it could easily evolve into “shadow banking”. Umar Farooq, Global Co-Head of Payments, and Peter Muriungi, CEO of Digital Assets and Blockchain Solutions at the company, issued a statement calling for the United States to establish a comprehensive digital asset framework, though without directly referencing the “Clarity Act”. The statement noted that “tokenization and programmable money” offer key innovations for global payments and 24/7 real-time settlement. However, yield-bearing stablecoins could veer into “shadow banking”, so stablecoins should be subject to “the same regulatory standards as traditional deposit products”.

Affected by this news, the company's stock price fell 5.9% after hours. The FDA has set a revised PDUFA (Prescription Drug User Fee Act) target action date for December 27, 2026, instead of the previous PDUFA date of September 27. This postponement occurred after Praxis submitted an additional sensitivity analysis regarding existing clinical data. The FDA has classified this submission as a major amendment, thereby allowing additional review time. The FDA has not requested any new clinical studies nor raised any concerns related to safety or manufacturing.

This move means that these securities components, which were previously issued as unit combinations, will now be able to be bought and sold separately. Investors will have greater flexibility in configuring their portfolios and can adopt independent trading strategies for different securities components. This change is expected to provide higher liquidity to the market and may impact the valuation and trading dynamics of related securities.